Your session is about to expire
← Back to Search
Neoadjuvant Pembrolizumab for Non-Small Cell Lung Cancer (TOP 1501 Trial)
TOP 1501 Trial Summary
This trial is studying two doses of pembrolizumab given before and after surgery to see if it can shrink tumors in people with early-stage non-small cell lung cancer.
TOP 1501 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTOP 1501 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183TOP 1501 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung cancer is at a stage where surgery is possible.I have a history of lung scarring or fibrosis.I have an active tuberculosis infection.You are currently in prison or are being held against your will for treatment of a mental or physical illness.My lung cancer diagnosis was confirmed through lab tests.I have an autoimmune disease treated with medication in the last 2 years.My doctor says I can have surgery.My organs are functioning well.I have been diagnosed with HIV.I have an immune system disorder or have been on steroids or other immune-weakening medicines in the last week.I have another cancer that is getting worse or needs treatment.I haven't received any treatment for my current lung cancer diagnosis.I am 18 years old or older.I haven't had any cancer except for non-melanoma skin cancer in the last 2 years.My lung function tests after surgery are expected to be above 40% of what's predicted.I haven't had major surgery in the last 2 weeks and don't have serious health issues that would make the study unsafe for me.I have received vaccines for preventing infections.I have had a heart attack in the last 6 months or have uncontrolled heart issues.I haven't used any unapproved drugs or devices in the last 30 days.I have a history of or currently have non-infectious lung inflammation.I am not receiving any other cancer treatments.I have an active Hepatitis B or C infection.You are allergic to pembrolizumab or any of its ingredients.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.I am currently on medication for an active infection.My primary tumor is larger than 3 cm.I am fully active or can carry out light work.You have a disease that can be measured using specific guidelines.
- Group 1: Pembrolizumab prior to and after surgery
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you please tell us about Pembrolizumab's clinical trial history?
"Out of the 1000 clinical trials utilising Pembrolizumab, 122 are currently in Phase 3. Though many of these studies originate from Houston, Texas; there are 36030 active locations for this treatment globally."
What are Pembrolizumab's common therapeutic applications?
"Pembrolizumab is a medication that oncologists often use to treat cancer. Additionally, it can be useful for patients with microsatellite instability high or those who have experienced disease progression after chemotherapy."
Are we looking for more test subjects at this time?
"Unfortunately, this particular clinical trial is not taking any more patients at the moment. Although, there are 2394 other trials that might be of interest and are currently recruiting participants."
How many test subjects are involved in this clinical trial?
"Unfortunately, this study is no longer seeking participants. If you were hoping to enroll in this trial, we encourage you to explore the other 1,394 trials actively recruiting patients with carcinoma or non-small-cell lung cancer."
What are some possible side effects of Pembrolizumab?
"While there is some evidence of safety, as this is a Phase 2 trial, Power rates the safety of Pembrolizumab at a 2."
Share this study with friends
Copy Link
Messenger